RT @medoncodoc: 🔬 CONTACT-02 Phase 3 Trial in mCRPC 🔬.📍 Patients with metastatic castration-resistant prostate cancer + extrapelvic soft-ti….

RT @urotoday: Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not al….

RT @medoncodoc: 🚨 New findings in metastatic hormone-sensitive prostate cancer (#mHSPC)! 🚨. 🔹 Over 12% of mHSPC patients harbor BRCA1/2 mut….

RT @oncodaily: Home from ASCO25 reflecting on transformative Prostate Cancer Research - @DCockrellMD .@ASCO . #Can….

Home from #ASCO25 reflecting on transformative #ProstateCancer research. My thoughts on some of the most impactful studies⬇️. Thankful for new data to discuss with pts w/ hope for longer, healthier lives. @ASCO @AarmstrongDuke @DukeGUCancer @oncodaily @urotoday @OncoAlert

RT @AarmstrongDuke: Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinical….

My take: We need to better utilize AI and real world data to help clarify patient characteristics that tailor treatment intensifications. Prospective RCTs are gold standard, but this field moves so quickly that SOC changes by completion. #bladdercancer #ASCO25.

Holy grail for #MIBC is finding bladder sparing curative systemic therapy. Can EV/pembro or gem/cis/durva patients with negative ctDNA keep their bladder, maybe with RT consolidation? Big questions to be answered in the next few years. #ASCO25

#MIBC management continues to get more complicated. Multidisciplinary evaluations are necessary. As confusing as this space is for oncologists and urologists, imagine the struggle for patients. Truly informed decisions are a challenge. Can we better risk stratify T2 disease?

#MODERN will hopefully help to address the issue of how to best utilize ctDNA. We know about the prognostic importance of ctDNA +/-, but can we better tailor treatment with a risk adapted, ctDNA guided approach? PDL1 hasn’t been very useful. #ASCO25

Utility of biomarkers like ctDNA, PDL1, and path staging will help better determine which patients actually benefit from adjuvant therapy now in the post-NIAGARA age. Expect updates from ctDNA this weekend. #ASCO25

#NIAGARA has brought a new era of immunotherapy into the neoadjuvant #bladdercancer space, but questions still remain about how much benefit there is from the adjuvant IO.

Here for a discussion on continuing advances in periooerative systemic therapy in muscle invasive #bladdercancer. Highlights to follow ⬇️ . #ASCO25.@OncoAlert .@UrologyToday .@GUOncologyNow

Here for a discussion on continuing advances in periooerative systemic therapy in muscle invasive #bladdercancer. Highlights to follow ⬇️ . #ASCO25.@OncoAlert .@UrologyToday .@GUOncologyNow

Here for a discussion on continuing advances in periooerative systemic therapy in muscle invasive #bladdercancer. Highlights to follow ⬇️ . #ASCO25.@OncoAlert .@UrologyToday .@GUOncologyNow

RT @rmistry91: So proud of this study and honored to be the senior author! . What we’ve learned: @TheFellowOnCall and @TwoOncDocs should be….

Thankful to have been part of this #MedEd study highlighting the benefits of @TheFellowOnCall and @TwoOncDocs podcasts in #HemOnc fellowships. See concurrent pub in @JCO_ASCO!. @vpatelmd @DrKarineTawagi @rmistry91 @MoriahF_MD .

RT @tompowles1: The 5 yr follow up for adjuvant pembro in RCC (KN564): continued benefit- DFS (5yr 52% v61% - HR0.71) OS (5yr 82% vs 88% H….

Day 2 #ASCO25 kicked off w/ a great discussion from @DrRanaMcKay of HIF-2α therapies in #RCC. Early success in refractory & VHL disease pave the way for earlier combination with IO/TKIs. Excited for @DrChoueiri's oral abstract tomorrow. @oncodaily .@OncoAlert .@GUOncologyNow

RT @TiansterZhang: Traveling w/ mixed emotions to @asco #asco25 this yr. Celebrating science & the yrs of dedication, work, & patient contr….